Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of January 2026, with a report date of January 21, 2026. Haleon Plc is a global leader in consumer health with a portfolio spanning six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company operates under the ticker symbols HLN on both the LSE and NYSE.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory notification regarding corporate governance and does not contain financial performance data.
Material Changes
The primary material change disclosed is a corporate governance appointment. Dawn Allen, Chief Financial Officer of Haleon, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective March 5, 2026. Ms. Allen has served as a Non-Executive Director of ITV plc and a member of its Audit & Risk Committee since October 2, 2023.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on performance, or discussion of risks and contingencies. The document strictly addresses the notification requirement under Listing Rule 6.4.9R(2) regarding the director's new role.
Key Facts for Investor Verification
- Dawn Allen, Haleon's CFO, will chair the Audit & Risk Committee of ITV plc starting March 5, 2026.
- This filing is a compliance notification and does not include financial results or operational updates for Haleon.
- Investors should verify if this external board role impacts Ms. Allen's availability or focus on Haleon's strategic initiatives.